Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis
Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior
Recently trial data has shown that the medicine KaftrioTM (Elexacaftor/ Tezacaftor/ Ivacaftor) improves lung function in children aged 6 to 11 years who have cystic fibrosis (CF).
- Trial name
- GIFT-CFJunior (NCT05699148)
- Testing
- Elexacaftor / Ivacaftor / Tezacaftor
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Cystic Fibrosis
Zoledronic Acid in Cystic Fibrosis
Null hypotheses: zoledronic acid does not improve bone density in cystic fibrosis. Low bone mineral density (osteoporosis) is prevalent in adults with cystic fibrosis (CF); they have an increased rate of bone fractures in…
- Trial name
- IZAC (NCT01702415)
- Testing
- Zoledronic acid
- Where
- United Kingdom
- Sponsor
- Papworth Hospital NHS Foundation Trust
Cystic Fibrosis
Glycemic Monitoring in Cystic Fibrosis
Current guidelines on the diagnoses and management of cystic fibrosis (CF) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes.
- Trial name
- GEM (NCT02211235)
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis, Cystic Fibrosis Liver Disease
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)
RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) triple combination therapy in people with cystic fibrosis initially…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication
- Trial name
- RECOVER (NCT04602468)
- Testing
- Elexacaftor/Tezacaftor/Ivacaftor
- Where
- 7 sites in Ireland, United Kingdom
- Volunteers
- 206 people
- Sponsor
- Royal College of Surgeons, Ireland
Cystic Fibrosis (CF), Chronic Kidney Disease(CKD)
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect kidney damage early before it…
- Conditions
- Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Acute Kidney Injury
- Trial name
- NCT06595420
- Where
- 3 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Cystic Fibrosis
Phase II Study of Digitoxin to Treat Cystic Fibrosis
This study will measure the inflammatory effects of digitoxin on IL-8 and neutrophil counts in induced sputum in stable Cystic Fibrosis (CF) patients and the pharmacokinetics of digitoxin in serum. Funding Source-FDA OOPD
- Trial name
- NCT00782288
- Testing
- digitoxin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Jewish Health
Cystic Fibrosis
The EPIC Observational Study
The purpose of this study is to better define risk factors preceding first isolation of Pseudomonas aeruginosa (Pa) from respiratory cultures in cystic fibrosis (CF) lung disease and to better define clinical outcomes associated…
- Trial name
- EPIC OBS (NCT00676169)
- Where
- 54 sites in United States
- Volunteers
- 1,248 people
- Sponsor
- CF Therapeutics Development Network Coordinating Center
Quality of Lifte, Cystic Fibrosis (CF)
Characterisation of a Population of Adults Suffering From Cystic Fibrosis in a Belgian Reference Center
This research project aims to better understand the consequences of diabetes on the quality of life, respiratory function, and nutritional status of patients with cystic fibrosis followed at a Belgian reference center and to…
- Conditions
- Quality of Lifte, Cystic Fibrosis (CF), Diabetes
- Trial name
- NCT07442682
- Where
- Belgium
- Volunteers
- 162 people
- Sponsor
- Erasme University Hospital
Exocrine Pancreatic Insufficiency
Phase 1 Study to Assess Safety and Efficacy of ANG003
Randomized, parallel, active-treatment Phase 1 study of a single dose of orally administered ANG003 with a test meal in adult subjects with cystic fibrosis-related exocrine pancreatic insufficiency.
- Trial name
- NCT06052293
- Testing
- ANG003
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Anagram Therapeutics, Inc.
Cystic Fibrosis
HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy
This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR).
- Trial name
- NCT04798014
- Where
- United States
- Volunteers
- 860 people
- Sponsor
- Indiana University
Exocrine Pancreatic Insufficiency
Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)
Protocol ALCT-0000497 is a multicenter safety, tolerability and fat absorption study that anticipates enrolling 35 male and female subjects (pediatric and adult) with cystic fibrosis.
- Trial name
- NCT02598128
- Testing
- RELiZORB
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alcresta Therapeutics, Inc.
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
The purpose of this study was to evaluate the safety and efficacy of ivacaftor in participants with cystic fibrosis (CF) who were aged 12 years or older and were homozygous for the F508del-CF transmembrane conductance regulator…
- Trial name
- DISCOVER (NCT00953706)
- Testing
- Ivacaftor
- Where
- 34 sites in United States
- Volunteers
- 140 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
Evaluate the safety and tolerability of VX-659 in healthy subjects
- Trial name
- NCT03029455
- Testing
- VX-659, Tezacaftor, Ivacaftor
- Where
- 10 sites in United Kingdom
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pulmonary Inflammation, Cystic Fibrosis
Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis
Pulmonary inflammation is an independent risk factor for disease progression in cystic fibrosis patients (CF). Yet, no effective treatment is known to reduce this detrimental inflammation.
- Conditions
- Pulmonary Inflammation, Cystic Fibrosis, Microbiota
- Trial name
- MoHuM-1 (NCT01837355)
- Testing
- Lactobacillus rhamnosus
- Where
- Switzerland
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Cantonal Hospital of St. Gallen
Cystic Fibrosis
Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients
Cystic Fibrosis is a genetic disease with variable severity, and a predisposition for lung infection. Usually severity is determined by the class of CF mutations, but even among patients with the same severity of mutations there…
- Trial name
- Hp-in-CF (NCT01806025)
- Testing
- no intervention
- Where
- Israel
- Volunteers
- 142 people
- Sponsor
- Carmel Medical Center
Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.
- Trial name
- NCT05153317
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 71 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)
For the Project VEMSE-CF, a comprehensive patient-centered outpatient health service model was developed offering focused interventions in different areas.
- Trial name
- VEMSE-CF (NCT03423576)
- Testing
- comprehensive patient-centered outpatient health service with multiple components
- Where
- Germany
- Volunteers
- 318 people
- Sponsor
- Mukoviszidose Institut gGmbH
Cystic Fibrosis
Determinants of Daily Physical Activity Level in Patients With Cystic Fibrosis - Pilot Study Protocol
The aim of the study is to analyze the determinants (barriers and facilitators) of the daily physical activity level in a population of patients with cystic fibrosis.
- Trial name
- APM (NCT05206097)
- Testing
- Accelerometer
- Where
- 6 sites in France
- Volunteers
- 87 people
- Sponsor
- University Hospital, Limoges
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.